Tocilizumab for the treatment of adult patients with severe COVID‐19 pneumonia: a single‐center cohort study
M Fernández‐Ruiz, F López‐Medrano… - Journal of medical …, 2021 - Wiley Online Library
Abstract Coronavirus disease 2019 (COVID‐19) can lead to a massive cytokine release. The
use of the anti‐interleukin‐6 receptor monoclonal antibody tocilizumab (TCZ) has been …
use of the anti‐interleukin‐6 receptor monoclonal antibody tocilizumab (TCZ) has been …
Clinical outcomes in COVID‐19 patients treated with tocilizumab: an individual patient data systematic review
D Antwi‐Amoabeng, Z Kanji, B Ford… - Journal of medical …, 2020 - Wiley Online Library
Background Current evidence suggests an important role of the interleukin‐6 (IL‐6) pathway
in severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)‐related cytokine …
in severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)‐related cytokine …
[HTML][HTML] Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial
T Karampitsakos, O Papaioannou, P Tsiri… - Clinical Microbiology …, 2023 - Elsevier
Objective Randomized controlled trials comparing tocilizumab and baricitinib in patients with
coronavirus disease 2019 (COVID-19) are needed. This was an open-label, randomized …
coronavirus disease 2019 (COVID-19) are needed. This was an open-label, randomized …
Why tocilizumab could be an effective treatment for severe COVID-19?
B Fu, X Xu, H Wei - Journal of translational medicine, 2020 - Springer
A severe pneumonia-associated respiratory syndrome caused by a new coronavirus was
identified in December 2019 (COVID-19), spread rapidly and has become a world-wide …
identified in December 2019 (COVID-19), spread rapidly and has become a world-wide …